Regeneron injects $100 million and 300 new roles into Irish production facility
Sanofi subsidiary Regeneron has announced its intention to expand its production plant in Limerick, Ireland – the largest scale bulk biologic production facility in the country – adding 300 new roles and injecting $100 million to energise operations through increasing drug substance production capacity to meet rising demands.
This latest move in the region pushes Regeneron well beyond its past projections – in 2015, the company noted that it expected its operations at the Raheen Industrial Estate, where the facility is located, to reach 500 by the end of 2017. Instead, with this latest move the workforce is now expected hit 800 by the end of 2018. So far, the company has injected $750 million into the region since 2014.
“Gut feel is a large portion of any site selection. When we picked Limerick years ago, we simply felt good about the community, universities and people,” commented Dan Van Plew, Executive Vice President and General Manager of Industrial Operations and Product Supply at Regeneron. “A few years and a lot of experience later, I can now confidently say I know Limerick is a place where you can build and thrive as a biotech.
“We are proud of what has happened here and the vast majority of this work has been completed by people who come from Munster,” he continued. “These folks built, validated and began production in a way I’d put up against any other team on the planet. We feel at home here and the way we have been welcomed has made our ongoing growth and investment in Limerick rewarding on the most personal levels.”
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …
Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing …